Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.
The altered pharmacokinetic properties of, e.g., aminoglycosides in cystic fibrosis patients have to be considered when pulmonary exacerbations are treated. Since reported data on ciprofloxacin, a fluorinated quinolone, are conflicting, we compared intravenous and oral administration in cystic fibro...
Uloženo v:
| Vydáno v: | Antimicrob Agents Chemother |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Microbiology (ASM)
1992
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC284363/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1489195/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.36.11.2512 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|